This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: In their Editorial accompanying the report of our trial of aptiganel for acute ischemic stroke,¹ Drs Becker and Tirschwell² make a number of important and valid points. However, several of their inferences about our study were based on incomplete information and thus require clarification.

First, the authors were concerned that patients enrolled in the study were not informed about the availability of thrombolytic therapy. After the US Food and Drug Administration approved intravenous tissue plasminogen activator (t-PA) for patients with ischemic stroke who could be treated within 3 hours of symptom onset, the informed consent of our study was modified to reflect this new information. There was no intent to deprive patients of any treatment (including intravenous t-PA) that their physicians deemed appropriate. Patients who were treated with t-PA were precluded from participation in the trial because of concern of untoward drug interactions. Treating physicians decided whether . . . [Full Text of this Article]

RELATED ARTICLES

Aptiganel Hydrochloride in Acute Ischemic Stroke: A Randomized Controlled Trial
Gregory W. Albers, Larry B. Goldstein, David Hall, Lynna M. Lesko, and for the Aptiganel Acute Stroke Investigators
JAMA. 2001;286(21):2673-2682.
ABSTRACT | FULL TEXT  

Ensuring Patient Safety in Clinical Trials for Treatment of Acute Stroke
Kyra J. Becker and David L. Tirschwell
JAMA. 2001;286(21):2718-2719.
EXTRACT | FULL TEXT